Compare G & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | G | INDV |
|---|---|---|
| Founded | 1997 | N/A |
| Country | Bermuda | United States |
| Employees | 140000 | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 4.4B |
| IPO Year | 2007 | 2014 |
| Metric | G | INDV |
|---|---|---|
| Price | $28.28 | $39.96 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $49.50 | N/A |
| AVG Volume (30 Days) | ★ 2.7M | 1.6M |
| Earning Date | 05-07-2026 | 06-08-2026 |
| Dividend Yield | ★ 2.21% | N/A |
| EPS Growth | 9.82 | ★ 8100.00 |
| EPS | ★ 0.86 | 0.69 |
| Revenue | ★ $2,279,438,000.00 | $1,239,000,000.00 |
| Revenue This Year | $9.20 | N/A |
| Revenue Next Year | $7.27 | N/A |
| P/E Ratio | ★ $32.69 | $55.54 |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $27.37 | $13.47 |
| 52 Week High | $48.64 | $41.00 |
| Indicator | G | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 31.84 | 65.83 |
| Support Level | N/A | $35.36 |
| Resistance Level | $35.09 | $41.00 |
| Average True Range (ATR) | 1.08 | 1.28 |
| MACD | -0.39 | 0.12 |
| Stochastic Oscillator | 17.15 | 97.52 |
Genpact Ltd is an agentic, technology-solutions company offering digital transformation, data-driven operations, and technology-enabled services across multiple industries. Its core business services include decision support services; technology services like application lifecycle management, platform customization, and support, etc; and digital operations optimizing business processes. Genpact also offers data engineering, data management, and domain-based AI and generative AI solutions; develops new technology solutions for clients; and offers agentic solutions and technology consulting services. Its reportable segments are: High Tech and Manufacturing, which generate maximum revenue, Financial Services, and Consumer and Healthcare. Geographically, it derives maximum revenue from India.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).